Suppliers / Aizant Drug Research Solutions

Aizant Drug Research Solutions

India 960 employees Updated 9 July 2026

Aizant Drug Research Solutions is a finished-dose manufacturer based in India. It appears in 47 regulatory filings across 7 regulators, without an active US DMF or CEP on file. Its filings concentrate with INVIMA (CO), ARCSA (EC) and US FDA. Its GMP standing is certified by EMA, EAEU_EEC and MFDS (Korea), among 5 authorities. Its most recent recorded inspection, by US FDA, closed on 14 November 2025 as VAI. Customs aggregates show $12.7M of exports covering 233 molecules to 28 destinations in 2025.

0
active US DMFs
0
valid CEPs
5
registered plants 2 with an FDA FEI number
47
filings across 7 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
2 of 2 confirmed
Inspections
7 of 7 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 14 November 2025 VAI US FDA
  • 28 April 2023 NAI US FDA
  • 25 January 2023 NAI US FDA
  • 24 January 2020 VAI US FDA
  • 3 May 2019 NAI US FDA
  • 15 March 2019 NAI US FDA
  • 13 July 2018 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Hyderabad, India 3025169808
Hyderabad, India 3008243902
TELANGANA, India Not on file
Medchal- Malkhajgiri District-500100, India Not on file
Hyderabad, India Not on file

Filings and GMP by regulator

Regulator Filings GMP certificates
INVIMA (CO) 16 None
ARCSA (EC) 11 None
US FDA 10 1
MINSA (CR) 6 None
NPRA (MY) 2 None
DIGEMAPS (DO) 1 None
EMA None 4
EAEU_EEC None 3
MFDS (Korea) None 2
ANVISA (Brazil) None 2

Scale

Year Revenue Exports Destinations
2026 YTD Not reported $1.9M 11
2025 Not reported $12.7M 28
2024 Not reported $10.3M 21
2023 Not reported $10.4M 21

Export figures are customs aggregates. We do not publish the identity of any buyer.

Comparing suppliers?

Choose your molecules and target markets. Aizant Drug Research Solutions comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 14 November 2025.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates
Customs aggregates
Export values, molecule and destination counts